![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 08, 2015 9:15:44 AM
100 Percent Protection Demonstrated in Preclinical Studies; Excellent Immune Responses and Safety Profile Observed
Sep 8, 2015, 1:04:00 PM
ATLANTA, GA - (NewMediaWire) - September 08, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced today that its investigational Ebola vaccine candidate, GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
"We are very pleased with the outcome of this study," commented Harriet L. Robinson, Ph.D., GeoVax's Chief Scientific Officer. "Through our ongoing research, we have anticipated that GeoVax's VLPs would elicit a strong immune response, and we had already demonstrated the production of Ebola VLPs in human cells. The next steps will be vaccination and challenge studies in nonhuman primates while also preparing for cGMP manufacturing of the vaccine for human clinical trials."
"GeoVax is committed to developing an Ebola vaccine with a superior safety and efficacy profile as compared to those of other vaccine candidates under development," said Robert T. McNally, Ph.D., GeoVax's President and Chief Executive Officer. "There are currently no approved vaccines for filoviruses (including Ebola virus) anywhere on the globe. The 2014/15 West African Ebola epidemic has caused over 28,000 infections, resulting in over 11,300 deaths. Considering the unpredictable and regular outbreaks of Ebolavirus infections, the development of vaccines that broadly protect against multiple filoviruses is a global priority. We believe our Ebola vaccine candidates have the potential to provide support in this effort, and we look forward to updating our shareholders as we move ahead."
About GeoVax's Ebola Vaccines
GeoVax began its Ebola vaccine development program in late 2014, using its non-infectious virus-like particle (VLP) technology and modified vaccinia Ankara (MVA) vector system originally developed for its HIV vaccine program. The Company first developed a vaccine for the recent epidemic in West Africa: a Zaire ebolavirus vaccine. In early 2015 the company expanded the program to include two other major filoviruses: Sudan Ebolavirus and Marburg virus, with the goal of developing a series of individual vaccines (monovalent) that will address each of the lethal strains of Ebola virus (Zaire, Sudan and Bundibugyo) and Marburg virus. The Company also plans to develop a multivalent vaccine, which will incorporate multiple monovalent vaccines to protect against the three strains of Ebola and Marburg with a single product. For testing purposes, GeoVax's first focus is on the monovalent vaccine for the Zaire strain of Ebola, designated GOVX-E301.
GeoVax's vaccine platform induces production of VLPs from the cells of the person receiving the vaccine. The production of VLPs in the person being vaccinated (in vivo) mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear. Producing VLPs in vivo also circumvents the need to purify virus-like particles for inoculation.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its novel vaccine platform. Current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). GeoVax believes its technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and intends to pursue expansion of its product pipeline.
Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's HIV vaccines, in various doses and combinations, have been tested in about 500 humans. For more information, go to www.geovax.com.
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM